External reports (aggregated public sources), Value Investors Club

Value Investors Club

Value Investors Club (.com) is an exclusive online investment club where top investors share their best ideas. Content available at the above link/PDF preview is an external article authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External reports (aggregated public sources)

Equity Bottom-Up

<ul><li>Biopharma company LABP targeted for takeover by AbbVie with offer of $20.42 cash per share and CVR potentially worth over $11</li><li>Deal valued at $137.5 million in cash and $75 million in contingent value rights, expected to close in Q2 2024</li><li>CVR presents opportunity for potentially lucrative payout but comes with risks associated with illiquid securities</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Biopharma company LABP targeted for takeover by AbbVie with offer of $20.42 cash per share and CVR potentially worth over $11Deal valued at $137.5 million in cash and $75 million in contingent value rights, expected to close in Q2 2024CVR presents opportunity for potentially lucrative payout but comes with risks associated with illiquid securitiesThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Landos Biopharma Inc (LABP) - Tuesday, Apr 16, 2024